[{"id":"1","company":"1","drug":"11","health_plan":"26","therapeutic_area":"Rheumatoid Arthritis","description":"Harvard Pilgrim's payment for Enbrel will depend on six effectiveness criteria, including patient compliance, switching or adding drugs, steroid interventions, and dose escalation. If patients taking Enbrel score below a specified level in the six effectiveness criteria, Harvard Pilgrim will pay less for Enbrel, as its real life effectiveness will have been lower. ","source":"1","year":"2017","year_fil":"2017","type":"Outcomes-Based Contracting","date":"2018-07-17 14:05:04","company_name":"Amgen","colour":"colour1","drug_name":"Enbrel (etanercept)","health_plan_name":"Harvard Pilgrim","source_desc":"\"Harvard Pilgrim To Pay for 2 Autoimmune Drugs Based on Outcomes, Value\", Managed Care, 2017"},{"id":"2","company":"1","drug":"12","health_plan":"26","therapeutic_area":"Hypercholesterolemia","description":"Upfront discounts and future rebates given with the promise of additional rebates if the patient meets specific cholesterol targets (if they did not experience reductions in LDL cholesterol levels comparable to those observed in the drugs preapproval clinical trials), the total spending threshold, and adherence in exchange for preferred formulary placement. \r\nA full refund is provided if the patient has a heart attack or stroke. ","source":"2","year":"2016 2017 (full refund)","year_fil":"2016","type":"Outcomes-Based Contracting","date":"2018-07-17 14:07:10","company_name":"Amgen","colour":"colour1","drug_name":"Repatha (evolocumab)","health_plan_name":"Harvard Pilgrim","source_desc":"Outcomes-Based Pharmaceutical Contracts: An Answer to High U.S. Drug Spending? Commonwealth Fund Issue Brief, September 2017"},{"id":"3","company":"1","drug":"12","health_plan":"27","therapeutic_area":"Hypercholesterolemia","description":"1) CVS health will get a discount if it keeps \"preferring\" Repatha - keeping the drug under the tier-1\/tier-2 formulary list. 2) The insurer will get an additional rebate if the drug fails to lower the cholesterol of patients to the degree indicated by the drugs clinical trials. The insurer will get a third rebate, if more patients are using the drug than was anticipated.","source":"3","year":"2015","year_fil":"2015","type":"Outcomes-Based Contracting","date":"2018-07-17 14:08:17","company_name":"Amgen","colour":"colour1","drug_name":"Repatha (evolocumab)","health_plan_name":"CVS Health","source_desc":"\"Developing a Path to Value-Based Payment for Medical Products; Value-Based Payment Advisory Group Kick-Off Meeting Background Paper\", Duke University, 2017"},{"id":"4","company":"1","drug":"12","health_plan":"28","therapeutic_area":"Hypercholesterolemia","description":"If Cigna-insured patients who take Repatha are not able to reduce LDL cholesterol levels at least as well as what was shown in clinical trials, Amgen will further discount the cost of the drug for all patients (not just those who did not meet their cholesterol goals). If Repatha exceeds expectations in patients, the original negotiated price that Cigna pays for the drug will remain in place.","source":"4","year":"2016","year_fil":"2016","type":"Value-Based Contracting","date":"2018-07-17 14:09:37","company_name":"Amgen","colour":"colour1","drug_name":"Repatha (evolocumab)","health_plan_name":"Cigna","source_desc":"\"Health Insurers Push to Tie Drug Prices to Outcomes\", The Wall Street Journal, 2016"},{"id":"5","company":"2","drug":"13","health_plan":"26","therapeutic_area":"Cardiovascular Diseases ","description":"1) AstraZeneca offers to cover a certain portion of treatment costs of patients who have additional heart attacks after taking the drug Brilinta if the rate of heart attacks exceeds an agreed threshold. 2) The threshold is calculated based on Brilinta's patient outcomes data showing the degree of heart attacks reduction in patient population.","source":"5","year":"2014 2017","year_fil":"2014","type":"Value-Based Contracting","date":"2018-07-17 14:11:51","company_name":"Astra Zeneca","colour":"colour2","drug_name":"Brilinta (ticagrelor)","health_plan_name":"Harvard Pilgrim","source_desc":"\"Developing a Path to Value-Based Payment for Medical Products; Value-Based Payment Advisory Group Kick-Off Meeting Background Paper\", Duke University, 2017; \"Harvard Pilgrim Signs Outcomes-Based Contracts with AstraZeneca for Brilinta and Bydureon\", BusinessWire (2017)"},{"id":"6","company":"2","drug":"14","health_plan":"26","therapeutic_area":"Type 2 Diabetes","description":"1) Harvard Pilgrim will measure HbA1c levels in patients and evaluate the ability of patients who adhere to Bydureon to get to a predetermined Hanc goal; 2) If Bydureon fails to meet the agreed upon outcomes criteria in patients, Harvard Pilgrim will be charged a lower amount by AstraZeneca for Bydureon. AstraZeneca and Harvard Pilgrim agree that the health plan will be charged for Bydureon based on value to the patient, not just based on volume of medicine sold.","source":"6","year":"2017","year_fil":"2017","type":"Outcomes-Based Contracting","date":"2018-07-17 14:12:42","company_name":"Astra Zeneca","colour":"colour2","drug_name":"Bydureon (exenatide extended-release)","health_plan_name":"Harvard Pilgrim","source_desc":"The U.S. OBIC Tracker, Stisali, updated May 2017"},{"id":"7","company":"2","drug":"15","health_plan":"29","therapeutic_area":"Breast and Lung Cancers","description":"1) If a patient stops treatment before the third prescription fill, AstraZeneca will fully reimburse Express Scrips for the Iressa costs of that patient. 2) This arrangement aims to encourage patient adherence, which will improve the utilization of the drug.","source":"3","year":"2015","year_fil":"2015","type":"Value-Based Contracting","date":"2018-07-17 14:13:28","company_name":"Astra Zeneca","colour":"colour2","drug_name":"Iressa (gefitinib)","health_plan_name":"Express Scripts","source_desc":"\"Developing a Path to Value-Based Payment for Medical Products; Value-Based Payment Advisory Group Kick-Off Meeting Background Paper\", Duke University, 2017"},{"id":"8","company":"3","drug":"16","health_plan":"30","therapeutic_area":"Cardiovascular Diseases ","description":"1) The basic structure is a pay-for-pill model. The payer and provider will negotiate a baseline price for each unit of Effient. 2) The drug price is adjusted by the hospitalization rate due to cardiovascular events for patients taking the drug. 3) If hospitalization rate is higher, the drug price will go down; if hospitalization rate is lower, the price will go up.","source":"3","year":"2014","year_fil":"2014","type":"Value-Based Contracting","date":"2018-07-17 14:14:14","company_name":"Eli Lilly","colour":"colour3","drug_name":"Effient (prasugrel tablets)","health_plan_name":"Humana","source_desc":"\"Developing a Path to Value-Based Payment for Medical Products; Value-Based Payment Advisory Group Kick-Off Meeting Background Paper\", Duke University, 2017"},{"id":"9","company":"3","drug":"17","health_plan":"26","therapeutic_area":"Osteoporosis ","description":"This contract rewards improvement in persistence in medication use as compared to the baseline level to adherence seen in the Harvard Pilgrim population. If Harvard Pilgrim patients see a meaningful improvement to their Osteoporosis, Eli Lilly will reduce the cost of the drug for Harvard Pilgrim. ","source":"7","year":"2017","year_fil":"2017","type":"Value-Based Contracting","date":"2018-07-17 14:55:48","company_name":"Eli Lilly","colour":"colour3","drug_name":"Forteo (teriparatide)","health_plan_name":"Harvard Pilgrim","source_desc":"\"Harvard Pilgrim Signs Value-Based Contract with Eli Lilly & Company for its Osteoporosis drug, Forteo\", Metro Hartford Alliance"},{"id":"10","company":"3","drug":"18","health_plan":"26","therapeutic_area":"Type 2 diabetes mellitus","description":"Harvard Pilgrim will pay Eli Lilly a lower net-price for Trulicity if fewer patients taking it achieve an HbA1c value of less than 8% compared with patients taking other GLP1 receptor agonists, and a higher net-price if patients taking Trulicity have better outcomes than patients taking other competing drugs.","source":"8","year":"2014","year_fil":"2014","type":"Outcomes-Based Contracting","date":"2018-07-17 14:57:25","company_name":"Eli Lilly","colour":"colour3","drug_name":"Trulicity (dulaglutide)","health_plan_name":"Harvard Pilgrim","source_desc":"Performance-Based Risk-Sharing Arrangements for Pharmaceutical Products in the United States: A Systematic Review"},{"id":"11","company":"4","drug":"19","health_plan":"31","therapeutic_area":"Non Small Cell Lung Cancer (NSCLC)","description":"Rebates are tied to progression-free survival (PFS) (a key endpoint in the phase 3 clinical trial); the shorter the PFS in a patient taking Avastin, the greater the rebate to Priority Health. If a patient saw no progression in lung cancer while taking Avastin after 6 months of adhering to the drug regiment, Priority Health would not receive a rebate.","source":"9","year":"2015","year_fil":"2015","type":"Outcomes-Based Contracting","date":"2018-07-17 14:58:47","company_name":"Genentech","colour":"colour4","drug_name":"Avastin (bevacizumab)","health_plan_name":"Priority Health","source_desc":"\"Overcoming Challenges of Outcomes-Based Contracting for Pharmaceuticals: Early Lessons from the Genentech - Priority Health Pilot\", Health Affairs Blog, 2017"},{"id":"12","company":"5","drug":"20","health_plan":"28","therapeutic_area":"Diabetes ","description":"1) Merck will increase the discount to Cigna, if there is a higher percentage of patients showing an improvement of blood sugar values by the end of the agreement period, compared to a negotiated baseline. 2) Merck will offer further discount to Cigna if a certain percentage of Cigna members meet the benchmark for medication adherence.","source":"3","year":"2009","year_fil":"2009","type":"Value-Based Contracting","date":"2018-07-17 15:47:30","company_name":"Merck & Co.","colour":"colour5","drug_name":"Januvia (sitagliptin) and Janumet (sitagliptin metformin HCL)","health_plan_name":"Cigna","source_desc":"\"Developing a Path to Value-Based Payment for Medical Products; Value-Based Payment Advisory Group Kick-Off Meeting Background Paper\", Duke University, 2017"},{"id":"13","company":"5","drug":"20","health_plan":"28","therapeutic_area":"Diabetes ","description":"Rebates are given if a specified A1 blood sugar level is not met in the patient population. The agreement is also contingent on good adherence. ","source":"2","year":"2009","year_fil":"2009","type":"Outcomes-Based Contracting","date":"2018-07-17 15:48:21","company_name":"Merck & Co.","colour":"colour5","drug_name":"Januvia (sitagliptin) and Janumet (sitagliptin metformin HCL)","health_plan_name":"Cigna","source_desc":"Outcomes-Based Pharmaceutical Contracts: An Answer to High U.S. Drug Spending? Commonwealth Fund Issue Brief, September 2017"},{"id":"14","company":"5","drug":"20","health_plan":"32","therapeutic_area":"Diabetes","description":"Merck\u2019s rebates on Januvia and Janumet will be based in part on those products\u2019 contributions to helping Aetna\u2019s commercial member population with type 2 diabetes achieve or maintain treatment objectives.","source":"10","year":"2016","year_fil":"2016","type":"Value-Based Contracting","date":"2018-07-17 15:49:25","company_name":"Merck & Co.","colour":"colour5","drug_name":"Januvia (sitagliptin) and Janumet (sitagliptin metformin HCL)","health_plan_name":"Aetna","source_desc":"\"Aetna and Merck Sign a Unique Value-Based Contract to Januvia and Janumet\", Aetna Press Release, October 2016"},{"id":"15","company":"6","drug":"21","health_plan":"33","therapeutic_area":"Multiple Sclerosis","description":"EMD Serono will pay rebates to Prime Therapeutics on its multiple sclerosis drug, Rebif, if: 1) Patients treated with Rebif have a higher overall total cost than patients treated on a different, older multiple sclerosis drug; 2) The patient adherence rate if Rebif remains above a specified level.","source":"11","year":"2012","year_fil":"2012","type":"Value-Based Contracting","date":"2018-07-17 15:50:39","company_name":"Merck (EMD Serono)","colour":"colour6","drug_name":"Rebif (interferon beta-1a)","health_plan_name":"Prime Therapeutics","source_desc":"Developing a Path to Value-Based Payment for Medical Products; Value-Based Payment Advisory Group Kick-Off Meeting Background Paper, 2017"},{"id":"16","company":"6","drug":"21","health_plan":"33","therapeutic_area":"Multiple Sclerosis","description":"Rebates are given if patients taking the drug have total costs to their plans higher than patients on a different MS drug, or if the medication adherence rate reaches a specified level.","source":"2","year":"2011","year_fil":"2011","type":"Outcomes-Based Contracting","date":"2018-07-17 15:51:32","company_name":"Merck (EMD Serono)","colour":"colour6","drug_name":"Rebif (interferon beta-1a)","health_plan_name":"Prime Therapeutics","source_desc":"Outcomes-Based Pharmaceutical Contracts: An Answer to High U.S. Drug Spending? Commonwealth Fund Issue Brief, September 2017"},{"id":"17","company":"7","drug":"22","health_plan":"34","therapeutic_area":"Congestive Heart Failure","description":"1) The payer and manufacturer agree on an initial baseline rebate for Entresto payment; 2) The payer and manufacturer use heart failure hospitalization rate as a key predictor of patient outcomes; 3) If the heart failure hospitalization rate of patients using Entresto exceed a pre-specified threshold, Novartis will reduce the price of Entresto to payers; 4) Conversely, if patients experience a lower rate of heart failure hospitalization, Novartis will charge a higher price for the drug.","source":"3","year":"2011","year_fil":"2011","type":"Outcomes-Based Contracting","date":"2018-07-17 15:52:57","company_name":"Novartis","colour":"colour7","drug_name":"Entresto (sacubitril\/valsartan)","health_plan_name":"Aetna\/ Cigna","source_desc":"\"Developing a Path to Value-Based Payment for Medical Products; Value-Based Payment Advisory Group Kick-Off Meeting Background Paper\", Duke University, 2017"},{"id":"18","company":"7","drug":"22","health_plan":"34","therapeutic_area":"Congestive Heart Failure","description":"Novartis partnered with Aetna to provide rebates based on rate of hospitalization for those using Entresto. Additional rebate is given if the drug does not achieve the heart failure admissions reductions it achieved during clinical trials. ","source":"2","year":"2016","year_fil":"2016","type":"Outcomes-Based Contracting","date":"2018-07-17 15:53:58","company_name":"Novartis","colour":"colour7","drug_name":"Entresto (sacubitril\/valsartan)","health_plan_name":"Aetna\/ Cigna","source_desc":"Outcomes-Based Pharmaceutical Contracts: An Answer to High U.S. Drug Spending? Commonwealth Fund Issue Brief, September 2017"},{"id":"19","company":"8","drug":"23","health_plan":"35","therapeutic_area":"Osteoporosis","description":"1) Proctor & Gamble and Sanofi-Aventis guarantee that Health Alliance plan beneficiaries who take Risedronate sodium will reduce their incidence of bone fracture. 2) If a patient still suffers from fracture after taking the drug (proving the drug's inefficacy), the manufacturer will reimburse the medical cost for treating the fracture.","source":"3","year":"2009","year_fil":"2009","type":"Value-Based Contracting","date":"2018-07-17 15:57:15","company_name":"Procter & Gamble\/ Sanofi-Aventis","colour":"colour8","drug_name":"Risedronate sodium","health_plan_name":"Health Alliance","source_desc":"\"Developing a Path to Value-Based Payment for Medical Products; Value-Based Payment Advisory Group Kick-Off Meeting Background Paper\", Duke University, 2017"},{"id":"20","company":"9","drug":"24","health_plan":"28","therapeutic_area":"Hypercholesterolemia","description":"If Cigna patients who take Praluent aren't able to reduce LDL cholesterol at least as well as what was shown in clinical trials, Sanofi \/ Regeneron will further discount the costs of the drugs for all patients (not just those who did not meet their cholesterol goals). If Praluent meets or exceeds expectations in patients, the original negotiated price will remain in place.","source":"4","year":"2016","year_fil":"2016","type":"Outcomes-Based Contracting","date":"2018-07-17 15:58:17","company_name":"Sanofi \/ Regeneron","colour":"colour9","drug_name":"Praluent (alirocumab)","health_plan_name":"Cigna","source_desc":"\"Health Insurers Push to Tie Drug Prices to Outcomes\", The Wall Street Journal, 2016"},{"id":"21","company":"9","drug":"24","health_plan":"29","therapeutic_area":"Hypercholesterolemia","description":"Sanofi\/Regeneron will lower the net price of Praluent\u00ae (alirocumab) Injection in exchange for becoming the exclusive PCSK9 inhibitor therapy on the Express Scripts national formulary. The agreement takes effect on July 1, 2018 for commercial patients covered by the Express Scripts National Preferred Formulary (approximately 25 million individuals in total). Physicians will submit a simplified attestation form confirming that Praluent is appropriate for the patient based on the U.S. FDA-approved indication and patient history. Express Scripts will pass a portion of the Praluent rebates it receives from Sanofi and Regeneron directly to people enrolled in participating commercial health benefit plans, including many of those offered by employers. Praluent's new price is reported to be $4,500 to $8,000 per year, the range recommended in March by the Institute for Clinical and Economic Review (ICER). The price reduction will come in the form of a rebate; the list price itself won't change.","source":"12","year":"2018","year_fil":"2018","type":"Outcomes-Based Contracting","date":"2018-07-17 16:11:47","company_name":"Sanofi \/ Regeneron","colour":"colour9","drug_name":"Praluent (alirocumab)","health_plan_name":"Express Scripts","source_desc":"http:\/\/www.news.sanofi.us\/2018-05-01-Sanofi-and-Regeneron-to-lower-net-price-of-Praluent-R-alirocumab-Injection-in-exchange-for-straightforward-more-affordable-patient-access-for-Express-Scripts-patients https:\/\/www.cnbc.com\/2018\/05\/01\/regeneron-sanofi-chop-cholesterol-drug-price-in-express-scripts-pact.html"},{"id":"22","company":"10","drug":"25","health_plan":"26","therapeutic_area":"Biallelic\u00a0RPE65\u00a0mutation-associated retinal dystrophy","description":"Spark Therapeutics will pay rebates to Harvard Pilgrim if patient outcomes fail to meet a specified threshold, considering both short term efficacy (30-90 days) and long-term durability (30 months). Short and long-term outcomes measures will be based on full-field light sensitivity (FST) testing scores. Since this is a one-time drug, outcomes will be determined on an individual basis. A baseline FST score will be established for each eligible patient before administration of Luxturna. If treatment fails, Harvard Pilgrim will receive a rebate from Spark Therapeutics. ","source":"13","year":"2018","year_fil":"2018","type":"Outcomes-Based Contracting","date":"2018-07-17 16:12:38","company_name":"Spark Therapeutics","colour":"colour10","drug_name":"Luxturna (voretigene neparvovec-rzyl)","health_plan_name":"Harvard Pilgrim","source_desc":"Outcomes-Based Contracts Offer Payers New Pharmaceutical Options,HealthPayer Intelligence, 2018; Spark Therapeutics Press Release, Jan 2018"}]